ReviewAAPS PharmSciTech2014
Advances in device and formulation technologies for pulmonary drug delivery.
Review in AAPS PharmSciTech, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed.
- In situ characterization of aerosol deposition in dry powder inhalers using optical coherence tomography.International journal of pharmaceutics · 2026Article
- Nanometer Layer Coating to Lactose Particles for Optimization of Dexamethasone Pulmonary Delivery.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Inhalation Dosage Forms: A Focus on Dry Powder Inhalers and Their Advancements.Pharmaceuticals (Basel, Switzerland) · 2023Review
- Amorphous Drug Nanoparticles for Inhalation Therapy of Multidrug-Resistant Tuberculosis.ACS nano · 2023Article
- Feedback systems in multi-dose dry powder inhalers.Postepy dermatologii i alergologii · 2023Review
- Tadalafil Nanoemulsion Mists for Treatment of Pediatric Pulmonary Hypertension via Nebulization.Pharmaceutics · 2022Article
- Spray Dried Rugose Lipid Particle Platform for Respiratory Drug Delivery.Pharmaceutical research · 2022Article
- The future of dry powder inhaled therapy: Promising or discouraging for systemic disorders?International journal of pharmaceutics · 2022Review
- Dry Powder Inhalers in the Digitalization Era: Current Status and Future Perspectives.Pharmaceutics · 2021Review
- Engineering Preclinical Tools and Therapeutics to Understand and Treat COVID-19.Delaware journal of public health · 2020Article
- Design and Characterizations of Inhalable Poly(lactic-Molecules (Basel, Switzerland) · 2020Article
- Advances in nanotechnology and asthma.Annals of translational medicine · 2019Review
- Improving the Efficiency of Respiratory Drug Delivery: A Review of Current Treatment Trends and Future Strategies for Asthma and Chronic Obstructive Pulmonary Disease.Pulmonary therapy · 2017Review
- Nebulised antibiotherapy: conventional versus nanotechnology-based approaches, is targeting at a nano scale a difficult subject?Annals of translational medicine · 2017Review
- Pulmonary delivery of nanoparticle chemotherapy for the treatment of lung cancers: challenges and opportunities.Acta pharmacologica Sinica · 2017Review
- Advanced Therapeutic Strategies for Chronic Lung Disease Using Nanoparticle-Based Drug Delivery.Journal of clinical medicine · 2016Review
- Understanding the Different Effects of Inhaler Design on the Aerosol Performance of Drug-Only and Carrier-Based DPI Formulations. Part 1: Grid Structure.The AAPS journal · 2016Article
- Drug Delivery Approaches in Addressing Clinical Pharmacology-Related Issues: Opportunities and Challenges.The AAPS journal · 2015Review
- Devices for dry powder drug delivery to the lung.AAPS PharmSciTech · 2015Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Inhaled pharmaceuticals are formulated and delivered differently according to the therapeutic indication. However, specific device-formulation coupling is often fickle, and new medications or indications also demand new strategies. The discontinuation of chlorofluorocarbon propellants has seen replacement of older metered dose inhalers with dry powder inhaler formulations. High-dose dry powder inhalers are increasingly seen as an alternative dosage form for nebulised medications. In other cases, new medications have completely bypassed conventional inhalers and been formulated for use with unique inhalers such as the Staccato® device. Among these different devices, integration of software and electronic assistance has become a shared trend. This review covers recent device and formulation advances that are forming the current landscape of inhaled therapeutics.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.